When Astrazenech’s flagship AstraZeneca vaccine hit the market in 2009, it was touted as a breakthrough for treating and preventing chronic conditions like asthma, diabetes, and cancer.

But a year later, the company revealed that the vaccine was linked to an outbreak of deadly pneumonia and diarrhea in at least 14 people.

The outbreak prompted the FDA to impose a recall of more than 40 million Astra Zeneca products, and Astra was forced to recall and replace more than 3 million of its vaccines by the end of the year.

At the time, the Astra brand had already been a target of criticism by vaccine manufacturers and consumer advocacy groups, as well as the pharmaceutical industry.

As the vaccine industry grappled with the fallout from the Astrazenevac outbreak, regulators, health care leaders, and the public clamored for more vaccines.

In 2014, lawmakers and advocates in Congress proposed an alternative plan to Astrazenax, which would have expanded access to the vaccine and provided a more effective treatment.

The bipartisan proposal was eventually dubbed the “Proteus Act.”

The proposal, which is called the Astrosavac Act, would have made a number of changes to Astra’s vaccine and would have provided a safer, more effective alternative to the Astrolax vaccine.

But even with this legislation, Astra faced an uphill battle.

The company has since come under intense scrutiny for safety and efficacy issues, particularly as the company faces regulatory scrutiny over the Astrazax outbreak.

In addition, Astrazenakes recent move to move its global operations from a large pharmaceutical to a smaller biotechnology division and move its manufacturing to Mexico has been met with backlash.

With the public pressure mounting on the company, the FDA last month ordered Astrazena to recall up to 100 million doses of Astra products.

Astra is also facing additional scrutiny after a study in which it admitted to violating the federal Food, Drug, and Cosmetic Act by marketing a brand of Astrazenka that contained a non-Hodgkin lymphoma drug.

The FDA has launched an investigation into the company’s compliance with the law.

Astrazenac has been under a regulatory review since its acquisition by Pfizer in 2017, and FDA officials have been warning for years that the company could face lawsuits.

The Astrazac Act has gained renewed momentum in recent years, however, with the public outcry over the vaccine-linked pandemic and the growing number of Astraza product recalls.

“The Astrazacs new CEO has been a strong proponent of the Astralax vaccine,” said Robert J. Casteel, the president and CEO of the National Vaccine Information Center, in a statement.

“His vision is to create a safe, effective vaccine that is backed by the strongest safety record in the industry.

He has demonstrated his commitment to safety and innovation and is dedicated to ensuring that all Astrazenaks products are safe and effective.”

In response to the new investigation, Pfizer issued a statement saying it will continue to develop a safe and safe vaccine that has proven to be effective for people.